Companies
GE
STOXX 600Health Care· Denmark
GMAB
DependentGenmab
$1,804.00
+0.78%
Open $1,778.50·Prev $1,790.00
as of 17 Apr
DEPENDENT
Power Core
Genmab's moat is genuine but narrow: its proprietary antibody engineering platforms, primarily DuoBody (bispecific antibodies) and HexaBody (hexameric antibody formats), produce molecules that larger pharmaceutical companies license because internal discovery cannot replicate the platform economics.
Published19 Apr 2026
UniverseSTOXX 600
SectorHealth Care
↑
Direction of Movement
lateral
ROC 200
+39.4%
GMAB
Genmab
$1,804.00
+0.78%
Open $1,778.50·Prev $1,790.00
as of 17 Apr
↓Overvalued by 352%
DCF Fair Value: $398.74
News
No recent news available.
Market data unavailable